European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyr
Community Register of medicinal products
Community register of orphan medicinal products | GRANTED |
Product information |
Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt
| EU orphan designation number: | EU/3/12/1036
|
| Active ingredient: | Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt |
| Indication: | Treatment of familial chylomicronaemia syndrome (type I hyperlipoproteinaemia) |
| Sponsor: | Novartis Europharm Limited
Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom |
Public summary of scientific opinion
European Commission procedures
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 18/09/2012 | Centralised Orphan - Designation | EMA/OD/071/12 | (2012)6514 of 14/09/2012 |